{
    "clinical_study": {
        "@rank": "154616", 
        "acronym": "UNCOVER-A", 
        "arm_group": [
            {
                "arm_group_label": "80 mg Ixekizumab Auto-Injector", 
                "arm_group_type": "Experimental", 
                "description": "Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection thereafter."
            }, 
            {
                "arm_group_label": "80 mg Ixekizumab Prefilled Syringe", 
                "arm_group_type": "Experimental", 
                "description": "Ixekizumab administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection thereafter."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the serum concentration of ixekizumab after\n      administration using either prefilled syringe or auto-injector in participants with moderate\n      to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety\n      extension."
        }, 
        "brief_title": "Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Plaque Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic\n             psoriasis vulgaris for at least 6 months prior to randomization\n\n          -  At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization\n\n          -  Static Physician Global Assessment (sPGA) score of at least 3 AND Psoriasis Area and\n             Severity Index (PASI) score of at least 12 at screening and at randomization\n\n          -  Candidate for phototherapy and/or systemic therapy\n\n          -  Men must agree to use a reliable method of birth control during the study\n\n          -  Women must agree to use birth control or remain abstinent during the study and for at\n             least 12 weeks after stopping treatment\n\n        Exclusion Criteria:\n\n          -  Pustular, erythrodermic, and/or guttate forms of psoriasis\n\n          -  History of drug-induced psoriasis\n\n          -  Clinically significant flare of psoriasis during the 12 weeks prior to randomization\n\n          -  Concurrent or recent use of any biologic agent\n\n          -  Received systemic psoriasis therapy [such as psoralen and ultraviolet A (PUVA) light\n             therapy] or phototherapy within the previous 4 weeks; or had topical psoriasis\n             treatment within the previous 2 weeks prior to randomization\n\n          -  Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks\n             prior to randomization and during the study\n\n          -  Have participated in any study with interleukin-17 (IL-17) antagonists, including\n             Ixekizumab\n\n          -  Serious disorder or illness other than plaque psoriasis\n\n          -  Serious infection within the last 3 months\n\n          -  Breastfeeding or nursing (lactating) women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777191", 
            "org_study_id": "14728", 
            "secondary_id": "I1F-MC-RHBL"
        }, 
        "intervention": [
            {
                "arm_group_label": "80 mg Ixekizumab Auto-Injector", 
                "description": "Administered SC by auto-injector", 
                "intervention_name": "Ixekizumab Auto-Injector", 
                "intervention_type": "Drug", 
                "other_name": "LY2439821"
            }, 
            {
                "arm_group_label": "80 mg Ixekizumab Prefilled Syringe", 
                "description": "Administered SC by prefilled syringe", 
                "intervention_name": "Ixekizumab Prefilled Syringe", 
                "intervention_type": "Drug", 
                "other_name": "LY2439821"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bakersfield", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93309"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90404"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33144"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ocala", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34471"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30327"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newnan", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30263"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington Heights", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60005"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Evansville", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47714"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Charles", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70605"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Methuen", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01844"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63117"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68144"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newington", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03801"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Windsor", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08520"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87104"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greensboro", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27408"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Exton", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19341"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wyomissing", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19610"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84132"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caguas", 
                        "country": "Puerto Rico", 
                        "zip": "00725"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Carolina", 
                        "country": "Puerto Rico", 
                        "zip": "00985"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ponce", 
                        "country": "Puerto Rico", 
                        "zip": "00716"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Puerto Rico"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ixekizumab After Starting Dose", 
                "safety_issue": "No", 
                "time_frame": "Day 2 to Day 14"
            }, 
            {
                "measure": "PK: Area Under the Concentration Time Curve from Time 0 to 14 Days (AUC 0-14) of Ixekizumab", 
                "safety_issue": "No", 
                "time_frame": "Day 2 to Day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777191"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy of Ixekizumab in Participants with Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index (PASI)", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Efficacy of Ixekizumab in Participants with Moderate to Severe Plaque Psoriasis. Measure: static Physician Global Assessment (sPGA)", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of Device Operation Failures", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Week 12"
            }, 
            {
                "measure": "Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 8"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}